2696 Shanghai Henlius Biotech, Inc. HKEX · China

Shanghai Henlius Biotech (2696) news

Shanghai Henlius Biotech, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2696, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Shanghai Henlius Biotech news

We have not published a story on Shanghai Henlius Biotech yet. When there is news, it will appear here.

Questions about Shanghai Henlius Biotech

What is the ticker symbol of Shanghai Henlius Biotech?

Shanghai Henlius Biotech, Inc. trades under the ticker 2696 on HKEX.

Where is Shanghai Henlius Biotech listed?

Shanghai Henlius Biotech, Inc. is listed on HKEX. Our directory also records these other listings: LSX:A2PRXP.

Which country or territory is Shanghai Henlius Biotech listed under?

Our directory records Shanghai Henlius Biotech, Inc. under China.

What does Shanghai Henlius Biotech do?

Our directory classifies Shanghai Henlius Biotech, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Shanghai Henlius Biotech?

The ISIN recorded for Shanghai Henlius Biotech, Inc. is CNE100003N76.

Does aibio.space cover Shanghai Henlius Biotech?

aibio.space lists Shanghai Henlius Biotech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Shanghai Henlius Biotech?

Companies in our directory listed in the same country and business area as Shanghai Henlius Biotech: Guizhou Xinbang Pharmaceutical Co., Cheng Du Sheng Nuo Biotec Co., Shanghai Allist Pharmaceuticals Co., Sunflower Pharmaceutical Group Co., Beijing Science Sun Pharmaceutical Co., Shandong Boan Biotechnology Company., Limited..

Investor discussion: Shanghai Henlius Biotech

Members talk about Shanghai Henlius Biotech (2696). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Shanghai Henlius Biotech, newest first. Each line links the filing it comes from.

Apr 24, 2026Financings
Share or debt issue: (1) ANNUAL REPORT 2025 (2) BOARD REPORT 2025 (3) BOARD OF SUPERVISORS REPORT 2025 (4) FINAL ACCOUNTS REPORT 2025 (5) PROFIT DISTRIBUTION PROPOSAL 2025 (6) RE-APPOINTMENT OF AUDITORS (7) REMUNERATIONS OF THE FULL-TIME EXECUTIVE DIRECTOR FOR THE YEAR 2025 (8) GRANT OF GENERAL MANDATE TO ISSUE SHARES (9) GRANT OF GENERAL MANDATE TO REPURCHASE H SHARES AND NOTICE OF AGM. Source
Apr 15, 2025Financings
Share or debt issue: ANNUAL GENERAL MEETING; RE-APPOINTMENT OF AUDITORS; GRANT OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE H SHARES; PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; NOTICES OF AGM. Source
Jan 22, 2025Listings
Trading status: JOINT ANNOUNCEMENT - (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING AND THE H SHAREHOLDERS' CLASS MEETING RELATING TO THE PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS AND (2) TERMINATION OF THE MERGER. Source
Jan 10, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 9, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 8, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 8, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 3, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 3, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 3, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 2, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 2, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Jan 2, 2025Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 31, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 31, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 31, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 30, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 30, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 30, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 27, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 24, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 23, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 22, 2024Mergers
Transaction under the Listing Rules: ELECTION FORM FOR THE CASH ALTERNATIVE OR THE SHARE ALTERNATIVE. Source
Dec 22, 2024Listings
Trading status: (1) PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS (2) PROPOSED WITHDRAWAL OF LISTING OF THE H SHARES OF HENLIUS (3) NOTICE OF THE EXTRAORDINARY GENERAL MEETING AND (4) NOTICE OF THE H SHAREHOLDERS' CLASS MEETING. Source
Dec 22, 2024Listings
Trading status: JOINT ANNOUNCEMENT - DESPATCH OF COMPOSITE DOCUMENT IN RELATION TO THE PROPOSED PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS. Source
Dec 20, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 19, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 18, 2024Mergers
Transaction under the Listing Rules: Disclosure of Dealings under Rule 22 of the Takeovers Code. Source
Dec 16, 2024Listings
Trading status: JOINT ANNOUNCEMENT - FULFILMENT OF THE PRE-CONDITIONS OF THE PROPOSED PRE-CONDITIONAL PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS. Source
Nov 22, 2024Listings
Trading status: JOINT ANNOUNCEMENT - PROGRESS UPDATE IN RELATION TO THE PRE-CONDITIONAL PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS. Source

Press releases

Headlines of Shanghai Henlius Biotech's own announcements, newest first. Each opens the full release on the newswire that carried it.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2696 on TradingView.

Listing details

Company: Shanghai Henlius Biotech, Inc.
Ticker: 2696
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: CNE100003N76
Other listed symbols: LSX:A2PRXP
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction